JOHN MARSHALL RENO
Pilots at Elm Dr, Lynnwood, WA

6709652, Mar 23, 2004

Aug 1, 2001

09/920454

John M. Reno - Brier WA
Louis J. Theodore - Lynnwood WA
Linda M. Gustavson - Seattle WA

NeoRx Corporation - Seattle WA

A61K 39395

4241411, 4241451, 4241531, 424 157, 424 165, 424 169, 424 173, 424 941, 4241791, 514 2, 514 44

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

6074659, Jun 13, 2000

Jul 10, 1998

9/113733

Lawrence L. Kunz - Redmond WA
Richard A. Klein - Lynnwood WA
John M. Reno - Brier WA
David J. Grainger - Cambridge, GB
James C. Metcalfe - Cambridge, GB
Peter L. Weissberg - Cambridge, GB
Peter G. Anderson - Birmingham AL

NoeRx Corporation - Seattle WA

A61F 200

424423

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

2002001, Jan 31, 2002

Jul 20, 2001

09/910388

Lawrence Kunz - Redmond WA, US
Richard Klein - Lynnwood WA, US
John Reno - Brier WA, US
David Grainger - Cambridge, GB
James Metcalfe - Cambridge, GB
Peter Weissberg - Cambridge, GB
Peter Anderson - Birmingham AL, US

NeoRx Corporation

A61K038/00, A01N037/18, A61K031/40, A01N043/38

514/012000, 514/002000, 514/411000

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

5616690, Apr 1, 1997

Oct 8, 1993

8/133613

Donald B. Axworthy - Brier WA
John M. Reno - Brier WA

NeoRx Corporation - Seattle WA

C07K 14765, C07K 1107, C07D23502

530363

Novel clearing agents comprising hexose derivatized human serum albumin and ligand molecule(s) are provided. These clearing agents are useful in pretargeting methods to clear previously administered anti-ligand containing conjugates. Preferably, the hexose is mannose or galactose and the ligand and anti-ligand are respectively biotin and avidin or streptavidin.

5976535, Nov 2, 1999

Jun 6, 1995

8/468513

Alan R. Fritzberg - Edmonds WA
Paul G. Abrams - Seattle WA
John M. Reno - Brier WA
Donald B. Axworthy - Brier WA
Scott S. Graves - Monroe WA
Sudhakar Kasina - Kirkland WA

NeoRx Corporation - Seattle WA

A61K 4505

4241821

Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.

2005000, Jan 13, 2005

Feb 25, 2004

10/787067

Scott Graves - Monroe WA, US
John Reno - Brier WA, US
Robert Mallett - Everett WA, US
Mark Hylarides - Stanwood WA, US
Stephen Searle - Cambridge, GB
Andrew Henry - Ely, GB
Jan Pedersen - Bronshoj, DK
Anthony Rees - St. Chaptes, FR

NeoRx Corporation - Seattle WA

A61K039/395, C07K016/44

424141100, 530388150

Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.

5981568, Nov 9, 1999

Mar 31, 1997

8/829685

Lawrence L. Kunz - Redmond WA
Richard A. Klein - Edmonds WA
John M. Reno - Brier WA

NeoRx Corporation - Seattle WA

A61K 3140

514411

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

2002013, Sep 26, 2002

Jul 30, 2001

09/919602

Sudhakar Kasina - Mercer Island WA, US
John Reno - Brier WA, US
Alan Fritzberg - Edmonds WA, US
Jonathan Tait - Seattle WA, US

A61K038/17, C07K014/435

514/008000, 530/395000

Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.

5283342, Feb 1, 1994

Jun 9, 1992

7/895588

Linda M. Gustavson - Seattle WA
Ananthachari Srinivasan - St. Charles MO
Alan R. Fritzberg - Edmonds WA
John M. Reno - Brier WA
Donald B. Axworthy - Brier WA

NeoRx Corporation - Seattle WA

A61K 4300, A61K 4902, C07D23500, C07D49504

5483041

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described.

5106951, Apr 21, 1992

Mar 31, 1989

7/332610

Alton C. Morgan - Edmonds WA
Ananthachari Srinivasan - Kirkland WA
John M. Reno - Brier WA
Alan R. Fritzberg - Edmonds WA
David C. Anderson - Seattle WA

NeoRx Corporation - Seattle WA

C07K 1700

5303919

There is disclosed an antibody and antibody-drug conjugate for targeting drug delivery as well as a class of chemicals, termed a drug-binding molecule of complementary structure (csDBM). The csDBM is designed to "fit" the drug by combining multiple non-covalent interactions between functional groups on the drug and opposing functional groups on the csDBM. The net result on the antibody-csDBM-drug conjugate is a drug stably bound to the csDBM so as not to dissociate during in vivo administration, but not so tightly bound to allow drug dissociation from the conjugate without significant loss of activity and retaining the drug's ability to bind to a higher affinity site on or within the target cell.